Table 1.xls (5.5 kB)
Baseline characteristics and corresponding primary efficacy outcomes of the Phase 3 trials included.
dataset
posted on 2018-05-24, 18:04 authored by Raghavendra Charan P. Makam, David C. Hoaglin, David D. McManus, Victoria Wang, Joel M. Gore, Frederick A. Spencer, Richeek Pradhan, Hoang Tran, Hong Yu, Robert J. GoldbergBaseline characteristics and corresponding primary efficacy outcomes of the Phase 3 trials included.
History
Usage metrics
Keywords
trial participantsFew meta-analysesvenous thromboembolismGIBNVAFConclusions PatientsSystematic reviewVTE randomizedDOAC recipientsDVTPEFDA-approved DOACnon-inferior efficacynon-valvular atrial fibrillationvitamin K antagonistsmeta-analysis BackgroundPhase 3 randomized trialsCIPooled Odds RatioFDA approvalsafety profileVKA